Evidence map›Paper›PMID 38895831›Full record

ArticleThe Journal of dermatology2024

Target area treatment ratio of varied lesions in the cultured pure melanocyte transplantation repigmentation of vitiligo: A retrospective study.

Fuquan Lin, Yunxia Wang, Yujie Zheng, Weisong Hong, Lifang Fu, Miaoni Zhou, Aie Xu

Abstract read
In one paragraph

Article in The Journal of dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fuquan LinDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID https://orcid.org/0000-0001-5268-4406
Yunxia WangDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yujie ZhengHangzhou Third People's Hospital Affiliated to the Zhejiang Chinese Medical University, Hangzhou, China.
Weisong HongDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0001-7412-6843
Lifang FuDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.
Miaoni ZhouDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.
Aie XuDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.

Funding

Hangzhou Medical Key Discipline Construction Project [2021]21-3National Natural Science Foundation of China 82003322National Natural Science Foundation of China U22A20310Natural Science Foundation of Zhejiang Province LY21H110002
6 · The paper itself

Abstract

Autologous cultured pure melanocyte transplantation (CMT) can be utilized to treat stable vitiligo cases, but clinical data are insufficient to improve its efficacy. To evaluate the influence of various factors on the therapeutic effect of CMT, this single-center retrospective study enrolled stable vitiligo patients who underwent CMT between 2009 and 2020. Univariate and multivariable analysis were used to determine the factors affecting the outcome of repigmentation. The study included 491 patients with long-term follow-up data (6-120 months). It was found that 69.7% of patients achieved an excellent re-color effect and 18.4% achieved a good re-color effect. There were statistically significant differences in pigmentation between patients with stable disease course, vitiligo type, and lesion site. Overall, a significant positive correlation between the target area treatment ratio of varied lesions and the percentage of repigmentation was found. CMT is effective and well tolerated in the treatment of stable vitiligo. Various factors, especially the target area treatment ratio of varied lesions, should be carefully assessed before using CMT. As the target area treatment ratio of varied lesions could further improve the post-operative repigmentation other than type of vitiligo. This clinic trial was approved by Hangzhou Third People's Hospital (number 2023KA015, national clinical record number MR-33-23-034502).

Indexed as

MelanocytesSkin PigmentationTransplantation, AutologousVitiligoAdolescentAdultCells, CulturedChildChild, PreschoolFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTreatment Outcomemelanocytesregionaltransplanationtreatment effectivenessvitiligo

Identifiers

PMID38895831
PMCPMC11483939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.